Suchergebnisse - "Shieh, Perry B"

PubPharm (10)

1

Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping : A randomized, double-blind, placebo-controlled, dose-titration trial

enthalten in: Muscle & nerve | 2021

von Wagner, K. | Kuntz, N. | Koenig, E. | +4

2

Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy : Results of the MoveDMD phase 2 and open label extension trial

enthalten in: Neuromuscular disorders : NMD | 2021

von Finkel, R. | Finanger, E. | Vandenborne, K. | +15

3

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping : PROMOVI Trial

enthalten in: Journal of neuromuscular diseases | 2021

von McDonald, C. | Shieh, P. | Abdel-Hamid, H. | +12

4

Large in-frame 5' deletions in DMD associated with mild Duchenne muscular dystrophy : Two case reports and a review of the literature

enthalten in: Neuromuscular disorders : NMD | 2019

von Gibbs, E. | Barthélémy, F. | Douine, E. | +6

5

Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation : A post HOC analysis from the ACT DMD trial

enthalten in: Muscle & nerve | 2018

von Shieh, P. | Mcintosh, J. | Jin, F. | +8

6

Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy

enthalten in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics | 2018

von Shieh, P.

7

Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy

enthalten in: Neurotherapeutics | 2018

von Shieh, P.

8

Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy

enthalten in: Neurotherapeutics | 2018

von Shieh, P.

9

Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy

enthalten in: NeuroRX | 2018

von Shieh, P.

10

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2017

von McDonald, C. | Campbell, C. | Torricelli, R. | +72

CommentIn: Lancet. 2017 Sep 23;390(10101):1467-1468. - PMID 28728957

1
[1]